Soares Lygia Maria Costa, de Medonça Ana Elza Oliveira, de Souza Dyego Leandro Bezerra, Carvalho Ariane Vieira, Flores Matheus Gonçalves, Neto Avelar Macedo, de Andrade Diocésio Alves Pinto, Rodrigues Angélica Nogueira
Postgraduate Program in Collective Health, Federal University of Rio Grande do Norte (UFRN), Natal, Rio Grande do Norte, Brazil; Department of Surgery, Federal University of Rio Grande do Norte (UFRN), Natal, Rio Grande do Norte, Brazil; Brazilian Group of Gynecologic Oncology (EVA), Brazil; LACOG (Latin American Cooperative Oncology Group), Brazil.
Postgraduate Program in Collective Health, Federal University of Rio Grande do Norte (UFRN), Natal, Rio Grande do Norte, Brazil; Department of Nursing, Federal University of Rio Grande do Norte (UFRN), Natal, Rio Grande do Norte, Brazil.
Vaccine. 2025 Jun 20;59:127278. doi: 10.1016/j.vaccine.2025.127278. Epub 2025 May 20.
HPV related tumors continue to be a global leading cause of cancer mainly due to cervical cancer (CC) burden. In Brazil, CC is the third most common cancer and the fourth highest cancer mortality rate among women. HPV vaccine mass immunization represents the current most promising intervention for CC prevention. It was first implemented in the Brazilian public health system in 2014, however, despite a history of excellent coverage for other vaccines, HPV vaccine uptake is below the necessary threshold for CC elimination. Identifying the factors that influence HPV vaccine hesitancy is an essential step to further develop strategies to improve vaccination coverage.
The aim of this study is to provide insights into whether or not Brazilians are resistant to HPV vaccination and to determine the factors and variables that influence this decision.
This is a population-based cross-sectional study which used quantitative methodology through personal interviews. A total of 2010 interviews were planned to result in error margins of 2 percentage points, more or less considering a 95 % confidence level, encompassing all five Brazilian regions. Cities of different sizes and complexities were included in the sample, as capitals and cities in both metropolitan and rural areas. The research was carried out with the Brazilian population aged 16 and over, interviewees were approached at points of population flow.
Between June 12th and 16th 2023, a total of 2010 personal interviews were done, with participants from all five Brazilian regions. The prevalence of vaccine resistance was 5.97 % (95 % confidence interval [CI], 4.93-7.23) among those interviewed. A multivariate analysis demonstrated greater resistance to the vaccine among men (prevalence ratios (PR): 1.58; 95 %CI 1.06-2.34; p: 0.023) and residents in the South region of the country (PR: 1.77; 95 %CI, 1.06-2.94; p: 0.028). The three main reasons for refusing the vaccine reported by the participants were: lack of knowledge about the HPV vaccine; difficulty in accessing the vaccine; and lack of vaccine prescription by health professionals. Safety was the main reason not to vaccinate, cited by 10 %.
Despite HPV vaccine availability in Brazil at the public health system, vaccination coverage remains below the target for both genders. However, according to this analysis, there is a low rate of HPV vaccination hesitancy in the country, being lack of knowledge, difficulty in accessing the vaccine and lack of vaccine prescription by health professionals the main obstacles to adequate adherence. The COVID-19 pandemic doesn't seem to have affected HPV vaccination resistance in the country. Proper strategies for vaccine implementation, including school-based programs, patient-provider communication and education, and integrated monitoring and evaluation strategies are needed, otherwise HPV vaccine programs run the risk of repeating the problems associated with Pap programs in Low- and Middle-Income Countries (LMICs): an efficient, life-saving tool underutilized for cancer prevention.
人乳头瘤病毒(HPV)相关肿瘤仍然是全球主要的癌症病因,这主要归因于宫颈癌(CC)的负担。在巴西,宫颈癌是女性中第三大常见癌症,癌症死亡率排名第四。HPV疫苗大规模免疫接种是目前预防宫颈癌最有前景的干预措施。2014年它首次在巴西公共卫生系统中实施,然而,尽管该国在其他疫苗接种方面历来有很高的覆盖率,但HPV疫苗的接种率仍低于消除宫颈癌所需的阈值。识别影响HPV疫苗犹豫的因素是进一步制定提高疫苗接种覆盖率策略的关键一步。
本研究旨在深入了解巴西人是否对HPV疫苗接种存在抵触,并确定影响这一决定的因素和变量。
这是一项基于人群的横断面研究,通过个人访谈采用定量方法。计划总共进行2010次访谈,考虑到95%的置信水平,误差幅度约为2个百分点,涵盖巴西所有五个地区。样本包括不同规模和复杂性的城市,如首都以及大都市和农村地区的城市。该研究针对16岁及以上的巴西人群开展,在人群流动点对受访者进行访谈。
在2023年6月12日至16日期间,共进行了2010次个人访谈,参与者来自巴西所有五个地区。在接受访谈者中,疫苗抵触率为5.97%(95%置信区间[CI],4.93 - 7.23)。多变量分析表明,男性(患病率比值(PR):1.58;95%CI 1.06 - 2.34;p:0.023)和该国南部地区居民(PR:1.77;95%CI,1.06 - 2.94;p:0.028)对疫苗的抵触情绪更强。参与者报告的拒绝接种疫苗的三个主要原因是:对HPV疫苗缺乏了解;难以获得疫苗;以及卫生专业人员未开具疫苗处方。安全性是10%的人提到的不接种疫苗的主要原因。
尽管巴西公共卫生系统中有HPV疫苗,但两性的疫苗接种覆盖率仍低于目标。然而,根据本分析,该国HPV疫苗犹豫率较低,缺乏知识、难以获得疫苗以及卫生专业人员未开具疫苗处方是充分接种的主要障碍。COVID - 19大流行似乎并未影响该国的HPV疫苗接种抵触情况。需要制定适当的疫苗实施策略,包括基于学校的项目、医患沟通与教育以及综合监测和评估策略,否则HPV疫苗项目可能会重蹈低收入和中等收入国家(LMICs)与巴氏涂片检查项目相关的问题:一种高效的、可挽救生命的癌症预防工具未得到充分利用。